Your browser is no longer supported. Please, upgrade your browser.
CKPT [NASD]
Checkpoint Therapeutics, Inc.
Index- P/E- EPS (ttm)-0.40 Insider Own5.00% Shs Outstand64.20M Perf Week-13.45%
Market Cap186.79M Forward P/E- EPS next Y-0.61 Insider Trans-3.50% Shs Float57.02M Perf Month-16.05%
Income-23.10M PEG- EPS next Q-0.12 Inst Own18.00% Short Float4.77% Perf Quarter-28.69%
Sales1.10M P/S169.81 EPS this Y40.90% Inst Trans5.76% Short Ratio1.96 Perf Half Y7.26%
Book/sh0.55 P/B4.56 EPS next Y-18.90% ROA-66.10% Target Price- Perf Year48.52%
Cash/sh0.55 P/C4.58 EPS next 5Y- ROE-84.40% 52W Range1.56 - 5.38 Perf YTD-5.28%
Dividend- P/FCF- EPS past 5Y21.80% ROI-65.50% 52W High-53.31% Beta1.66
Dividend %- Quick Ratio5.90 Sales past 5Y12.60% Gross Margin- 52W Low61.10% ATR0.20
Employees10 Current Ratio5.90 Sales Q/Q8.00% Oper. Margin- RSI (14)37.25 Volatility10.58% 7.23%
OptionableYes Debt/Eq0.00 EPS Q/Q24.80% Profit Margin- Rel Volume1.54 Prev Close2.36
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume1.39M Price2.51
Recom1.70 SMA20-11.49% SMA50-18.41% SMA200-11.11% Volume2,134,167 Change6.36%
Jan-20-21Initiated Cantor Fitzgerald Overweight $16
May-29-19Initiated Lake Street Buy
Dec-08-17Initiated H.C. Wainwright Buy $11
May-08-21 04:23AM  
May-06-21 04:15PM  
Mar-09-21 04:30PM  
01:19AM  
Mar-04-21 08:00AM  
Mar-01-21 08:30AM  
Feb-11-21 11:16AM  
Jan-06-21 08:30AM  
Dec-09-20 12:15AM  
Nov-27-20 01:06PM  
Nov-09-20 08:00AM  
Nov-04-20 04:25PM  
Nov-02-20 07:00AM  
Oct-25-20 09:08AM  
Sep-19-20 10:01AM  
Sep-17-20 05:27PM  
06:30AM  
Sep-14-20 07:19AM  
Sep-10-20 08:00AM  
Sep-08-20 10:02AM  
05:26AM  
Aug-17-20 08:00AM  
Aug-05-20 04:30PM  
Jul-27-20 07:30AM  
Jul-21-20 06:59AM  
Jul-16-20 03:27PM  
May-27-20 01:42PM  
May-22-20 08:30AM  
May-20-20 08:33AM  
May-09-20 08:41AM  
May-06-20 04:30PM  
Apr-27-20 07:00AM  
06:52AM  
Apr-21-20 08:00AM  
Mar-13-20 07:04AM  
Mar-11-20 04:15PM  
Mar-02-20 06:31AM  
Jan-13-20 08:15AM  
Dec-31-19 06:43AM  
Nov-21-19 07:22AM  
Nov-20-19 09:20AM  
Nov-19-19 04:01PM  
Nov-08-19 07:30AM  
Nov-07-19 04:30PM  
Oct-27-19 09:33AM  
Sep-30-19 07:30AM  
Sep-26-19 08:30AM  
Sep-16-19 07:30AM  
Sep-11-19 03:23PM  
Sep-04-19 08:30AM  
Aug-08-19 04:30PM  
Jul-12-19 03:47PM  
Jul-01-19 08:30AM  
May-09-19 05:00PM  
May-07-19 11:03AM  
May-02-19 10:32AM  
May-01-19 07:30AM  
Apr-29-19 09:05AM  
Apr-03-19 08:30AM  
Mar-15-19 07:30AM  
Mar-13-19 08:30AM  
Jan-07-19 08:30AM  
Dec-25-18 02:39PM  
Nov-02-18 09:15AM  
08:00AM  
Oct-26-18 10:30AM  
Oct-16-18 08:00AM  
Oct-09-18 01:54PM  
Sep-27-18 08:00AM  
Sep-25-18 08:00AM  
Sep-07-18 12:25PM  
Sep-06-18 07:30AM  
Aug-30-18 08:00AM  
Aug-13-18 10:30AM  
08:00AM  
Aug-08-18 07:30AM  
Aug-07-18 04:30PM  
Aug-02-18 10:29AM  
Jun-28-18 10:25AM  
Jun-04-18 08:00AM  
May-10-18 04:30PM  
Apr-18-18 09:00AM  
Apr-05-18 08:38AM  
Mar-21-18 08:00AM  
Mar-19-18 07:40AM  
Mar-15-18 04:05PM  
07:30AM  
Mar-13-18 07:45AM  
Mar-08-18 09:00AM  
Mar-07-18 04:05PM  
Feb-06-18 08:30AM  
Jan-03-18 07:30AM  
Dec-14-17 07:30AM  
Dec-08-17 10:42AM  
Dec-06-17 02:20PM  
Oct-05-17 09:00AM  
07:30AM  
Sep-20-17 08:00AM  
Sep-12-17 11:00AM  
Sep-11-17 08:30AM  
Checkpoint Therapeutics, Inc., a clinical-stage immuno-oncology biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to programmed death ligand-1 (PD-L1) and blocks the PD-L1 interaction with the programmed death receptor-1 and B7.1 receptors; and CK-302, a human agonistic antibody that is designed to bind to and trigger signaling in GITR expressing cells. It is also developing CK-101, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a treatment for patients with EGFR mutation-positive non-small cell lung cancer; CK-103, a selective and potent small molecule inhibitor of bromodomain and extra-terminal bromodomains; and anti-carbonic anhydrase IX (CAIX) antibody, a fully human preclinical antibody to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. Checkpoint Therapeutics, Inc. has collaboration agreements with TG Therapeutics, Inc. to develop and commercialize certain assets in connection with its licenses in the field of hematological malignancies. The company was incorporated in 2014 and is based in New York, New York. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Oliviero James F IIICEO, President and DirectorFeb 05Sale3.4248,790166,7453,153,210Feb 05 08:16 PM
Oliviero James F IIICEO, President and DirectorFeb 04Sale3.5170,000245,5253,202,000Feb 05 08:16 PM
GRAY WILLIAM GARRETTChief Financial OfficerFeb 04Sale3.6626,32096,318482,170Feb 05 08:16 PM
GRAY WILLIAM GARRETTChief Financial OfficerDec 22Sale2.792,4066,712357,490Dec 23 09:30 PM